Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
SciDev8d
Six-in-one vaccine vital to guard against 100-day cough
Comprehensive coverage of the hexavalent vaccine can protect again whooping cough and polio writes Esther Nakkazi.
Nasdaq18d
Sanofi Launches Beyfortus Immunization Against RSV For Infants In Canada This Fall
(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...
Yahoo Finance19d
Beyfortus® immunization to protect infants from RSV has begun
Six out of 10 infants and newborns in Canada will have access to the protective antibody Beyfortus ® for the first time this season ...
Seeking Alpha21d
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...
FiercePharma21d
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...
Benzinga.com22d
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...
Reuters22d
Sanofi profit growth beats market view on early start of vaccine sales
Oct 25 (Reuters) - French drug maker Sanofi (SASY.PA), opens new tab on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than ...
Business Insider22d
Sanofi (SNYNF) Gets a Hold from J.P. Morgan
In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target of €100.00. The company’s shares closed ...
ENDPOINTS NEWS22d
Sanofi backs fi­bro­sis biotech Agomab as it rais­es $89M Se­ries D
Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.
U.S. News & World Report22d
Sanofi Profit Growth Beats Market View on Early Start of Vaccine Sales
(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.
BioPharma Dive22d
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus, its RSV ...